Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 14 EP applications Karen Dorothee Larbig has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after August 15, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11779278

PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR

IPC classification:
A61K 47/38, A61K 47/26, A61K 47/20, A61K 31/444, A61K 9/20
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
EXAMINATION IN PROGRESS
EP12756614

USE OF ORGANIC COMPOUND FOR THE TREATMENT OF NOONAN SYNDROME

IPC classification:
A61K 31/166, A61P 43/00
Applicant:
Novartis AG
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12758966

PHARMACEUTICAL COMPOSITIONS COMPRISING AN AROMATASE INHIBITOR

IPC classification:
A61K 31/4196, A61K 9/48, A61P 35/00, A61P 15/08, A61P 5/26
Applicant:
Novartis AG
Agent:
Lionel Paul Clarke, Gill Jennings & Every LLP
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
PATENT GRANTED
EP12758965

USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES

IPC classification:
A61K 31/4196, A61K 9/48, A61P 15/08, A61P 5/26
Applicant:
Novartis AG
Agent:
Lionel Paul Clarke, Gill Jennings & Every LLP
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
PATENT GRANTED
EP13750725

NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING

IPC classification:
A61K 45/06, A61K 31/4192, A61K 31/216, A61K 31/197, A61K 31/194
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13832514

NEW PROCESS

IPC classification:
C07C 215/20, C07C 213/00
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14761702

NEW USE

IPC classification:
A61P 9/10, A61P 9/12, A61K 31/221, A61K 31/41, A61K 31/216, A61K 31/197, A61K 31/194, A61K 45/06
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13759384

NEW USE

IPC classification:
A61P 9/10, A61P 9/12, A61K 31/216, A61K 31/197, A61K 31/194, A61K 45/06
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
EXAMINATION IN PROGRESS
EP16157767

PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR

IPC classification:
A61K 9/20, A61K 31/216, A61K 9/00
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16704711

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS

IPC classification:
C07C 335/16, C07C 227/04, C07C 201/12
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
Request for examination was made
EP16722388

SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING HEART FAILURE

IPC classification:
A61P 9/08, A61K 31/41, A61K 31/225
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
Request for examination was made
EP16726663

SACUBITRIL AND VALSARTAN FOR TREATING METABOLIC DISEASE

IPC classification:
A61P 3/10, A61P 3/06, A61K 31/41, A61K 31/216
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
Request for examination was made
EP15744416

SACUBITRIL CALCIUM SALTS

IPC classification:
A61P 9/00, A61K 31/221, C07C 229/34
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma GmbH
Status:
Request for examination was made
EP16763586

NEW USE

IPC classification:
A61P 9/12, A61P 9/00, A61K 31/437, A61K 31/41, A61K 31/225
Applicant:
Novartis AG
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature